WGO Guidance for the Care of Patients with COVID-19 and Liver Disease

Saeed Hamid, Mario R. Alvares Da Silva, Kelly W. Burak, Tao Chen, Joost P.H. Drenth, Gamal Esmat, Rui Gaspar, Douglas Labrecque, Alice Lee, Guilherme Macedo, Brian Mcmahon, Qin Ning, Nancy Reau, Mark Sonderup, Dirk J. Van Leeuwen, David Armstrong, Cihan Yurdaydin

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the least deadly but most infectious coronavirus strain transmitted from wild animals. It may affect many organ systems. Aim of the current guideline is to delineate the effects of SARS-CoV-2 on the liver. Asymptomatic aminotransferase elevations are common in coronavirus disease 2019 (COVID-19) disease. Its pathogenesis may be multifactorial. It may involve primary liver injury and indirect effects such as "bystander hepatitis," myositis, toxic liver injury, hypoxia, and preexisting liver disease. Higher aminotransferase elevations, lower albumin, and platelets have been reported in severe compared with mild COVID-19. Despite the dominance of respiratory disease, acute on chronic liver disease/acute hepatic decompensation have been reported in patients with COVID-19 and preexisting liver disease, in particular cirrhosis. Metabolic dysfunction-associated fatty liver disease (MAFLD) has a higher risk of respiratory disease progression than those without MAFLD. Alcohol-associated liver disease may be severely affected by COVID-19 - such patients frequently have comorbidities including metabolic syndrome and smoking-induced chronic lung disease. World Gastroenterology Organization (WGO) recommends that interventional procedures such as endoscopy and endoscopic retrograde cholangiopancreatography should be performed in emergency cases or when they are considered strictly necessary such as high risk varices or cholangitis. Hepatocellular cancer surveillance may be postponed by 2 to 3 months. A short delay in treatment initiation and non-surgical approaches should be considered. Liver transplantation should be restricted to patients with high MELD scores, acute liver failure and hepatocellular cancer within Milan criteria. Donors and recipients should be tested for SARS-CoV-2 and if found positive donors should be excluded and liver transplantation postponed until recovery from infection.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalJournal of Clinical Gastroenterology
Issue number1
Publication statusPublished - Jan 2021


  • COVID-19 disease
  • autoimmune liver diseases
  • chronic viral hepatitis
  • hepatocellular carcinoma
  • liver disease
  • liver transplantation
  • metabolic dysfunction-associated liver disease


Dive into the research topics of 'WGO Guidance for the Care of Patients with COVID-19 and Liver Disease'. Together they form a unique fingerprint.

Cite this